Evaluating flotetuzumab, a bispecific CD3xCD123 antibody, and magrolimab, a CD47 antibody, together with azacitidine in patients with AML and MDS, respectively, revealed also high remission rates in TP53 aberrant subgroups [41, 42]. The gene discussed is TP53; the disease is acute myeloid leukemia.